my account log out | |
Setipiprant |
Create: 07/11/2019 |
Expired Date: | 12/31/2019 |
Category: | Drugs&Pharmaceutical [Health&Medical&Pharmaceutical] |
Message: | Setipiprant (ACT-129,968, KYTH-105) is a drug acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). It was initially researched as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients, it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application. Web: www.rawsgear.com Web: www.rawsgearpharma.com Email: gear@quality-steroid.com Skype: +8615711952876 Whatsapp +8615711952876 |
City: | Wuhan Hubei[CN] |
Location: | |
Jul 11 2019 | Clonidine hydrochloride | 215 | |
Jul 11 2019 | Phenacetin | 210 | |
Jul 11 2019 | CRL-40,940 | 210 | |
Jul 11 2019 | Pregabalin (4-Methylpregabalin) | 211 | |
Jul 11 2019 | Phenylacetonitrile | 199 | |
Jul 11 2019 | DMBA (1,3-Dimethylbutylamine hydrochloride) | 207 | |
Jul 11 2019 | DMHA (1,5-dimethyl-hexylamin) | 220 | |
Jul 11 2019 | DMAA (1,3-Dimethylamylamine) | 220 | |
Jul 11 2019 | Setipiprant | 214 | |
Jul 11 2019 | 1,3-dimethyl-butylamine citrate | 216 |
Copyright © 2012-2017 toextrade Inc. All rights reserved. Contact us DeepData© |